Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Persistent hyperparathyroidism after kidney transplantation is a global challenge, with historical wide incidence rates ranging from 8% to 58%, linked to pre transplant dialysis duration and hyperparathyroidism severity. The characteristics of secondary hyperparathyroidism in populations with predominantly live related donors having short waiting times (<1year) needs further investigations. The same has been primarily focused in this research work.
The objective of this study is to determine the frequency and identify the factors influencing persistent secondary hyperparathyroidism in a contemporary cohort of live related renal transplant recipients at a high volume center in Pakistan.
We conducted a cross–sectional study of 200 stable adult recipients, 6-24 months post-transplant at SIUT, Pakistan. Patients with graft failure were excluded. Persistent secondary hyperparathyroidism was defined as parathyroid hormone (P.T.H) > 108pg/ml (2 x upper normal limit. All participants’ underwent biochemical profiling (P.T.H, calcium phosphate, alkaline phosphatase, serum creatinine) and radiographic bone surveys.
The cohort (mean age 31 ± 9 years; 76% male had excellent allograft function (mean creatinine 1.35± 0.36mg/dl). The frequency of persistent secondary hyperparathyroidism was 20.5% (41/200). Hyper-calcemia and hypophosphatemia were present in 10.5% and 22.5% of the overall cohort respectively. Remarkably, multivariate analysis revealed no significant association between secondary hyperparathyroidism and traditional risk factors, including pre transplant dialysis duration (p=0.45), current graft function (p=0.52) or time since transplant (p=0.61). The only significant predictor was male sex (p<0.01) with a 3.4;1 male to female ratio in the cohort.
In a live related transplant programme with short waiting times (i.e. renal transplant are being conducted < 1 year at SIUT), we observed a lower incidence of persistent secondary hyperparathyroidism and a notable dissociation from its classic risk factors. This suggests a distinct phenotype of post-transplant bone disease in this setting, potentially influenced by rapid transplantation. The strong male predominance warrants further genetic or hormonal investigation. Hypogonadism occurs in both male and females with terminal renal failure. An explanation could be female skeleton is protected due to the effect of estrogen. Our findings advocate for region specific management protocols that move beyond paradigms established in populations with longer dialysis exposure.
